This development has allowed for a reduction in the size of the Phase 3 pivotal trial protocol evaluating the Annamycin in combination with Cytarabine for the treatment of Acute Myeloid Leukemia ...

The MIRACLE trial will evaluate Annamycin in combination with Cytarabine for patients with AML who have not responded to or have relapsed after initial therapy. The study employs an adaptive ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

This early unblinding will involve 30 participants receiving the combination of annamycin and cytarabine ... gains approval for enrolment in trial of AML therapy in Ukraine" was originally ...

Annamycin's approval in AML alone would bring the potential to ... in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad ...